The FDA on March 19, 2024, granted accelerated approval to ICLUSIG® (Ponatinib) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). ICLUSIG® is a product of Takeda Pharmaceuticals U.S.A., Inc.
Bottom Ad
Advertisement
Subscribe
